This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Onyx Pharma Is For Sale, for North of $10B

Stocks in this article: ONXX AMGN SNY PFE

Updated with stock prices.

SOUTH SAN FRANCISCO ( TheStreet) -- Onyx Pharmaceuticals (ONXX) is in play now that Amgen's (AMGN) $10 billion offer has been rejected as too low, so how much will it cost Amgen or another suitor to acquire the company?

Amgen's initial offer of $120 per share in cash was a 38 percent premium to Onyx's closing stock price of $86.82 on Friday. Onyx rejected the offer Sunday, saying it "significantly undervalued" the company, but also said it would seek out competitive offers from interested suitors.

Onyx is worth about $110 per share as a standalone company today, but if a competitive bidding situation ensues, the company could be acquired for as much as $148 per share, Deutsche Bank analyst Robyn Karnauskas said in a research note published Sunday.

Onyx shares opened Monday trading up 51% to $131.

It's common for initial takeout offers to be raised over time. Sanofi (SNY) first bid $69 per share for Genzyme. Following negotiations between the two companies, the final acquisition price bumped up to $74 per share plus a contingent value right tied to the performance of a Genzyme drug. Likewise, Roche (RHHBY) was forced to raise initial offer for Genentech before closing the deal.

"In our opinion, this $120 per share offer could be Amgen's effort to bring both parties to the negotiation table," Karnauskas writes, suggesting Amgen isn't likely to give up on acquiring Onyx.

An Amgen offer for Onyx valued at $140 per share would be 5 percent dilutive to earnings in 2014 and mildly accretive in 2015, Karnauskas writes.

Onyx in partnership with the German drug firm Bayer sells the kidney and liver cancer drug Nexavar and the colon cancer drug Stivarga. On its own, Onyx sell Kyprolis, used to treat multiple myeloma.

Onyx reported 2012 revenue of $362 million. The company's revenue is expected to grow to $624 million this year, $881 million in 2014 and $1.2 billion in 2015, according to consensus analyst estimates compiled by S&P Capital IQ.

Onyx is expected to lose $1.85 per share on an adjusted basis this year but generate a profit of 51 cents per share in 2014 and $3.79 per share in 2015, according to consensus analyst estimates compiled by S&P Capital IQ.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs